All canine diagnoses

Your dog was diagnosed with Multicentric B-Cell Lymphoma (Rescue/Relapse). Virtually all dogs with multicentric lymphoma will relapse after first-line therapy. Median first remission duration with CHOP is 6-11 months. Second remissions are typically shorter than first. Compare 8 treatment options for dogs including Rabacfosadine (Tanovea-CA1), CCNU (Lomustine) Rescue, MOPP Protocol — with survival times, costs, and what to expect during treatment.

🐕

Multicentric B-Cell Lymphoma (Rescue/Relapse)

WHO Stage III-V

BreedsGolden RetrieverBoxerBullmastiffBernese Mountain DogRottweiler
canine

Round Cell

About This Cancer

When a dog with B-cell lymphoma initially responds to chemotherapy but the cancer later returns, this is termed a relapse. Treatment given at this point is called rescue therapy. Unfortunately, virtually all dogs treated for multicentric lymphoma will eventually relapse, typically after a first remission lasting six to eleven months. At relapse, the cancer cells may have developed some resistance to the drugs used initially, which is why second-line ('rescue') protocols use different agents. Second remissions can usually be achieved, but they tend to be shorter than the first, and each successive remission becomes progressively harder to obtain and briefer in duration. The choice of rescue protocol depends on which drugs were used first line, how long the first remission lasted, and the dog's overall condition. Despite the challenges, many dogs can still enjoy a good quality of life for several additional months with appropriate rescue therapy.

WHO Clinical Staging for Canine Lymphoma

Same staging system as first-line. Re-staging at relapse is important to assess disease extent.

Stage ISingle lymph node or single extranodal site involvement
Stage IIMultiple lymph nodes in a regional area
Stage IIIGeneralised lymph node involvement
Stage IVLiver and/or spleen involvement
Stage VBlood, bone marrow, or non-lymphoid organ involvement
Prognostic Factors(4)
Duration of first remissionDogs with first remission >6 months generally respond better to rescue protocols than those with shorter first remissions
Number of prior treatment linesResponse rates and remission duration decrease with each successive rescue protocol
ImmunophenotypeB-cell still has better prognosis than T-cell in the rescue setting. Rabacfosadine response rates higher for B-cell.(Rassnick et al., 2022)
Prior doxorubicin exposure / cumulative doseArguably the most important factor in rescue planning. Dogs approaching the cumulative doxorubicin limit (180 mg/m²) cannot safely receive CHOP re-induction or doxorubicin-containing rescue protocols. Limits treatment options to non-anthracycline agents (rabacfosadine, CCNU, mitoxantrone). Echocardiography required before any further anthracycline exposure.(Vail DM, Thamm DH, Liptak JM (eds), 2020)
Minimum Workup(5 steps)
1CRITICAL WARNING: Avoid administering prednisolone/prednisone BEFORE obtaining biopsy/cytology — corticosteroids can induce multi-drug resistance (MDR) and cause rapid tumour lysis, making subsequent histopathological diagnosis difficult or impossible. Complete diagnostic workup BEFORE starting any corticosteroid therapy.
2Confirm relapse with fine-needle aspirate cytology
3Re-staging: CBC, biochemistry, thoracic radiographs, abdominal ultrasound
4Reassess immunophenotype if not previously determined
5Cardiac assessment if prior doxorubicin exposure

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Rabacfosadine (Tanovea-CA1)
See notes
CCNU (Lomustine) Rescue
See notes
MOPP Protocol
See notes
CHOP Re-induction
See notes
L-Asparaginase Single-Agent Rescue
See notes
LAP Protocol (L-Asparaginase + CCNU + Prednisone)
See notes
Mitoxantrone Rescue
See notes
Metronomic Cyclophosphamide (Palliative/Maintenance)
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.